**Question:** The drug which is not suitable for patients with acute porphyria for intravenous induction is –

A. Thiopental
B. Propofol
C. Midazolam
D. Fentanyl

**Correct Answer:** D. Fentanyl

**Core Concept:**
Acute porphyria is a group of rare genetic disorders that affect the liver, leading to the buildup of porphyrins, which can cause severe pain, neurological symptoms, and potentially life-threatening complications. In these patients, the use of certain medications can lead to a porphyriacrisis, worsening their symptoms and potentially leading to organ failure or death.

**Why the Correct Answer is Right:**
Fentanyl is a potent opioid agonist and a synthetic analog of morphine. In patients with acute porphyria, it can trigger porphyriacrisis by inhibiting the enzymes responsible for the breakdown of porphyrins, leading to an exacerbation of symptoms and potential organ failure.

**Why Each Wrong Option is Incorrect:**

A. Thiopental: This is a barbiturate, a class of drugs that share similar pharmacological properties, including inducing anesthesia. However, thiopental does not directly trigger porphyriacrisis, so it is less likely to cause severe complications in porphyria patients.

B. Propofol: A commonly used anesthetic agent, propofol does not directly trigger porphyriacrisis. Although it can deplete porphyrins, the risk is lower compared to fentanyl due to its short half-life and less potent inhibition of porphyrin-degrading enzymes.

C. Midazolam: A benzodiazepine, midazolam is another anesthetic agent that can deplete porphyrins but does not directly trigger a porphyriacrisis in patients with acute porphyria.

**Clinical Pearls and Pitfalls:**

1. **Clinical Pearls:** Understanding the pharmacology of anesthetic agents is crucial when treating patients with acute porphyria. Choosing the right medication reduces the risk of porphyriacrisis and associated complications.
2. **Clinical Pitfalls:** Misdiagnosis or inadequate management of acute porphyria can lead to severe complications and high morbidity/mortality rates. It is crucial to consider this rare genetic disorder when selecting anesthetic agents for patients presenting for surgery or other medical procedures.